Abstract Competition Winners
First Place (Tied)
Abstract #17 – David Geffen School of Medicine at UCLA
Title: MRI Visibility Stratifies Risk of Grade Group Progression and Treatment Initiation in Prostate Cancer Active Surveillance
Submitted by: Bhavesh H. Patel, MD
AND
Abstract #22 – Technical University of Munich, School of Medicine & Health
Title: Agreement and Prediction of Response of 18F-rhPSMA-7.3 (Flotufolastat) PET vs. Post-Therapy Scintigraphy to 177Lu-PSMA Radioligand Therapy in APMR Prostate Cancer
Submitted by: Sonia Grigorascu
AND
Abstract #9 – David Geffen School of Medicine at UCLA
Title: PSMA PET/CT and MRI for Determining Focal Therapy Eligibility in Patients with Prostate Cancer: Cohort Study with Histopathologic Validation
Submitted by: Zahra Mohammadigoldar, MD
Second Place
Abstract #19 – Cleveland Diagnostics, Inc.
Title: Diagnostic Performance of the IsoPSA Assay for Detection of High-Grade Prostate Cancer in Men with Total PSA 4–10 ng/mL Stratified by Pre-Biopsy MRI Status: No MRI and Non-Directive MRI (PI-RADS 1–3)
Submitted by: Mark Stovsky, MD, MBA, FACS
Third Place (Tied)
Abstract #13 – Holy Spirit University of Kaslik, Lebanon
Title: AI at the Tumor Board: Benchmarking Three Mainstream Chatbots Against Mirrors of Medicine Uro-Oncology Experts
Submitted by: Anthony Mina, MD, MPH
AND
Abstract #15 – Yale School of Medicine
Title: Initial Single-Center Experience with MRI-Guided TULSA-Pro for Localized Prostate Cancer: Early Oncologic Outcomes and Learning Curve
Submitted by: Andrea Lopez Sanmiguel
Fourth Place
Abstract #8 – Blue Earth Diagnostics & Mayo Clinic
Title: Impact of Clinical Factors on 18F-Piflufolastat and 18F-Flotufolastat Detection Rates in Participants with Recurrent Prostate Cancer Post-prostatectomy: Results from an Intra-patient Head-to-head Phase 4 Study
Submitted by: Jack R. Andrews, MD